A new generation of weight-loss medications that suppress patients’ appetites and make them feel full is facing reluctance among patients because of safety issues with past diet drugs.
The latest, Saxenda, from Novo Nordisk A/S, was approved by U.S. regulators late last year and hasn’t hit pharmacies yet. Other new appetite-suppressing prescription drugs on the market include Qsymia, Belviq and Contrave. Sales of the drugs have been slower than expected.
Also read: Rockies re-sign Jake McGee